Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06645197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

Name: An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis — clinical trial record (NCT06645197)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALS

StatusNot Yet Recruiting

PhaseEarly Phase 1

SponsorPeking University Third Hospital

Started2024-10-16

View on ClinicalTrials.gov ↗

Record status

This record was last updated October 16, 2024 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.

Peking University Third Hospital

219 trials monitored

See 3 trials at risk

ALS

384 trials monitored

See 17 trials at risk

This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).

Trial Details

NCT Number	NCT06645197
Lead Sponsor	Peking University Third Hospital Collaborators: SineuGene Therapeutics Co., Ltd.
Conditions	Amyotrophic Lateral Sclerosis (ALS)
Enrollment	7 participants
Start Date	2024-10-16
Primary Completion	2025-04-15 (estimated)
Study Completion	2029-10-15 (estimated)
Updated on ClinicalTrials.gov	2024-10-16